Nizatidine
| (nye-ZAT-ih-deen) |
Axid AR, Axid Pulvules, Apo-Nizatidine |
| Class: Histamine H2 antagonist |
Action Reversibly and competitively blocks histamine at H2 receptors, particularly those in gastric parietal cells, leading to inhibition of gastric acid secretion.
Indications Treatment and maintenance of duodenal ulcer, gastroesophageal reflux disease (GERD, including erosive or ulcerative disease) and benign gastric ulcer. Prevention of heartburn, acid indigestion and sour stomach brought on by consuming food and beverages.
Contraindications Hypersensitivity to H2 antagonists.
Duodenal Ulcer (Active)
ADULTS: PO 300 mg at bedtime or 150 mg bid for up to 8 wk; maintenance: 150 mg at bedtime.
Benign Gastric Ulcer (Acute)
ADULTS: PO 300 mg at bedtime or 150 mg bid.
GERD
ADULTS: PO 150 mg bid.
Moderate-to-Severe Renal Insufficiency
Dosage adjustment recommended.
Acid Reduction
ADULTS: PO 75 mg with water ½ to 1 hr before consuming food and beverages that may cause symptoms.
Aspirin Increased salicylate levels in patients taking very high doses of aspirin (3.9g/day). Ketoconazole Effects of ketoconazole may be reduced.
Lab Test Interferences False-positive tests for urobilinogen with Multistix may occur.
CV: Cardiac arrhythmias. CNS: Headache; somnolence; fatigue; dizziness. GI: Diarrhea; constipation; nausea; vomiting; abdominal discomfort; anorexia; cholestatic or hepatocellular effects. GU: Hyperuricemia unassociated w/gout or nephrolithiasis. HEMA: Thrombocytopenia; eosinophilia. HEPA: Hepatocellular injury; elevated AST, ALT and alkaline phosphatase concentrations. DERM: Exfoliative dermatitis; erythroderma; rash; pruritus; urticaria. OTHER: Gynecomastia; sweating; fever.
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Elderly: May have reduced renal function; decreased clearance may be more common. Hepatic impairment: Use drug with caution; decreased clearance may occur. In patients with normal renal function and uncomplicated hepatic dysfunction, nizatidine disposition is generally normal. Hepatocellular injury: Abnormalities appear to be reversible after discontinuation of drug. Renal function impairment: Decreased clearance may occur; reduced dosage may be needed.
| PATIENT CARE CONSIDERATIONS |
|
- Give twice daily after breakfast and at bedtime, or if once daily, give at bedtime.
- Do not administer within 1 hr of antacids.
- Store at room temperature.
- Obtain patient history, including drug history and any known allergies.
- Assess baseline AST, ALT, and alkaline phosphatase levels.
- Monitor liver function test results, CBC, BUN, and creatinine levels.
- Assess for constipation and encourage increased fluid intake.
- Assess for fatigue, somnolence, skin rashes, and diaphoresis
- Advise patient to take medication after breakfast and at bedtime if prescribed for twice-daily regimen or at bedtime if prescribed for once-daily dosage.
- Caution patient to stay active and to increase fluid and roughage in diet to prevent constipation.
- Instruct patient to take missed dose as soon as possible, and caution not to double doses.
- Advise patient to avoid cigarette smoking, which increases gastric acid secretions and therefore decreases effectiveness of nizatidine therapy.
- Instruct patient to report the following symptoms to physician: Abdominal pain, coffee-ground emesis, tarry stools, extreme fatigue, or weakness.
Popularity: 1% [?]
Apo-Nizatidine
Route/Dosage
Interactions
Adverse Reactions
Precautions
Administration/Storage
Assessment/Interventions
Patient/Family Education